Lymphomas
BGB-11417-303/CLL-RR1 / A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Details
ClinicalTrials.gov ID:
NCT05057494
Diagnosis Type:
NA
USOR Number:
- Address
,
P: